gmp
gmp

Find Ophthalmology Drugs in Phase I/II Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AR-15512

            Therapeutic Area: Ophthalmology Product Name: AVX012

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 29, 2020

            Details:

            The active ingredient in AR-15512 is a potent and selective agonist of the TRPM8 cold thermoreceptor ion channel that regulates tear production and blink rate. The acceptance of the IND for AR-15512 marks the first clinical-stage dry eye product candidate for Aerie.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IVMED-80

            Therapeutic Area: Ophthalmology Product Name: IVMED-80

            Highest Development Status: Phase I/ Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: National Eye Institute

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Series B Financing August 25, 2020

            Details:

            These investments will be used to advance the clinical development programs for the treatment of keratoconus and pediatric high myopia and adult low myopia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TTHX1114

            Therapeutic Area: Ophthalmology Product Name: NM141

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 19, 2020

            Details:

            The Phase 1/2 trial (“INTREPID”) is designed to evaluate TTHX1114’s safety and ability to stimulate the regeneration of corneal endothelial cells lost due to CED when administered by intracameral (back of the cornea) injection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EDIT-101

            Therapeutic Area: Ophthalmology Product Name: AGN-151587

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination August 06, 2020

            Details:

            Etidas has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the treatment of Leber congenital amaurosis 10.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Retinal pigment epithelium cell transplant therapy

            Therapeutic Area: Ophthalmology Product Name: OpRegen

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Israel Innovation Authority

            Deal Size: $16.0 million Upfront Cash: Undisclosed

            Deal Type: Funding July 06, 2020

            Details:

            As a result of continued clinical progress, the Israel Innovation Authority has extended its previously awarded development grant in support of OpRegen®, Company’s retinal pigment epithelium cell transplant therapy in development for the treatment of dry AMD.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Retinal pigment epithelial cells

            Therapeutic Area: Ophthalmology Product Name: OpRegen

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 18, 2020

            Details:

            The company has restarted patient enrollment in a Phase 1/2a study of OpRegen a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Retinal pigment epithelial cells

            Therapeutic Area: Ophthalmology Product Name: OpRegen

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 17, 2020

            Details:

            Lineage Cell Therapeutics will provide an update on the status of Lineage’s lead program, OpRegen®, an allogeneic retinal pigment epithelium (RPE) transplant therapy for dry age-related macular degeneration (AMD).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OpRegen RPE Cells

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 01, 2020

            Details:

            Restoration of retinal tissue was observed in a patient enrolled in a Phase 1/2a study of its lead product candidate, OpRegen®, a retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of dry age-related macular degeneration (AMD).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OpRegen

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 06, 2020

            Details:

            The presentation showcases results from a Phase I/IIa study of Lineage's lead product, OpRegen®, a retinal pigment epithelium cell transplant therapy for the treatment Dry AMD with Geographic Atrophy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RGX-314

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 22, 2020

            Details:

            RGX-314 continues to be well-tolerated at all dose levels . Long-term, durable treatment effect demonstrated over two years in Cohort 3.

            PharmaCompass